Clinic
Aurora Medical Center Bay Area, INC
Aurora Medical Center Bay Area, INC was paid $9.68M by Medicaid between Jan 2018 and Dec 2024, across 211 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoAURORA MEDICAL CENTER BAY AREA, INC
MARINETTE, WI 54143
MARINETTE, WI 54143
33aNPI1043397177assigned 11/01/2006
33bProvider typeRehabilitation Clinic/Center
28Total paid$9.68M
24GClaims453,463
24DCodes billed211
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Wisconsin
Rank by total paid#2 of 41
Median peer was paid$122K
This provider vs. median80×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,209 | $1.20M | |
| 2019 | 68,789 | $1.31M | |
| 2020 | 50,005 | $1.20M | |
| 2021 | 74,028 | $1.72M | |
| 2022 | 75,260 | $1.58M | |
| 2023 | 74,627 | $1.52M | |
| 2024incomplete | 50,545 | $1.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 14,139 | 12,677 | $1.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 12,193 | 10,693 | $956K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 9,092 | 7,810 | $956K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 6,739 | 5,447 | $663K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.0% | 6,465 | 5,092 | $584K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 14,256 | 4,835 | $425K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 3,959 | 3,618 | $353K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 4,024 | 3,674 | $266K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 3,632 | 3,266 | $263K |
| 80053 | Comprehensive metabolic panel | 2.7% | 23,160 | 17,808 | $260K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 3,164 | 2,243 | $204K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 8,197 | 6,477 | $197K |
199 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 4,034 | $153K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,976 | $150K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 1,817 | $150K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 31,010 | $149K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 1,579 | $142K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 4,704 | $138K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 1,711 | $131K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,305 | $114K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 802 | $95K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,489 | $90K |
| 83880 | <1% | 4,055 | $88K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,095 | $86K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,888 | $83K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,749 | $83K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,746 | $81K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 905 | $77K |
| 84484 | <1% | 9,761 | $70K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,305 | $68K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,626 | $64K |
| 97161 | <1% | 1,640 | $63K | |
| 84145 | <1% | 3,935 | $56K | |
| 82077 | <1% | 2,716 | $52K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 781 | $52K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,973 | $51K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,657 | $48K |
| 83605 | <1% | 6,861 | $47K | |
| 97597 | <1% | 1,363 | $46K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,148 | $46K |
| 83735 | <1% | 12,151 | $45K | |
| 80061 | Lipid panel | <1% | 1,227 | $44K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,588 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,417 | $36K |
| G0378 | Hospital observation service, per hour | <1% | 2,912 | $36K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,672 | $36K |
| 81025 | <1% | 5,126 | $32K | |
| 83690 | <1% | 7,959 | $32K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 241 | $32K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 430 | $31K |
| 86850 | <1% | 1,498 | $29K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,402 | $28K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 882 | $24K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 898 | $23K |
| 85379 | <1% | 3,487 | $21K | |
| 87040 | <1% | 2,570 | $21K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 853 | $20K |
| 76830 | Ultrasound, transvaginal | <1% | 473 | $20K |
| 96367 | <1% | 539 | $19K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 251 | $19K |
| 85610 | <1% | 5,837 | $17K | |
| 82962 | <1% | 4,682 | $17K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 83 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,059 | $16K |
| 81001 | <1% | 7,317 | $16K | |
| 80076 | <1% | 2,482 | $15K | |
| 70496 | <1% | 134 | $15K | |
| 86900 | <1% | 1,552 | $15K | |
| 84702 | <1% | 618 | $15K | |
| 82728 | <1% | 1,166 | $13K | |
| 85730 | <1% | 3,770 | $12K | |
| 81003 | <1% | 4,600 | $12K | |
| 87081 | <1% | 554 | $11K | |
| 80143 | <1% | 1,070 | $11K | |
| 97162 | <1% | 286 | $11K | |
| 71250 | <1% | 286 | $11K | |
| 82607 | <1% | 702 | $10K | |
| 87077 | <1% | 1,218 | $10K | |
| 70498 | <1% | 144 | $10K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 53 | $10K |
| 80179 | <1% | 1,014 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 439 | $9K |
| 85027 | <1% | 1,972 | $9K | |
| 86140 | <1% | 2,639 | $9K | |
| 93971 | <1% | 227 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 285 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 285 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 742 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 152 | $8K |
| A0425 | Ground mileage, per statute mile | <1% | 199 | $7K |
| 82805 | <1% | 253 | $6K | |
| 87186 | <1% | 1,216 | $6K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 64 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 809 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 282 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 482 | $5K |
| 80050 | General health panel | <1% | 366 | $5K |
| 85652 | <1% | 2,428 | $4K | |
| 0240U | <1% | 178 | $4K | |
| 90715 | <1% | 403 | $4K | |
| 74018 | <1% | 365 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $3K |
| 97165 | <1% | 101 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,291 | $3K |
| 86803 | <1% | 284 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 76 | $3K |
| 87340 | <1% | 381 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,835 | $3K |
| 83550 | <1% | 564 | $3K | |
| 64493 | <1% | 13 | $3K | |
| 86901 | <1% | 1,553 | $3K | |
| 84439 | <1% | 331 | $2K | |
| 72141 | <1% | 26 | $2K | |
| 76770 | <1% | 24 | $2K | |
| 83540 | <1% | 638 | $2K | |
| 97113 | <1% | 48 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 41 | $2K |
| 12001 | <1% | 35 | $2K | |
| 82746 | <1% | 236 | $2K | |
| 84703 | <1% | 331 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 27 | $2K |
| 93017 | <1% | 101 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 55 | $2K |
| 87070 | <1% | 187 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 476 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 27 | $2K |
| 87807 | <1% | 85 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,372 | $1K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $1K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $1K |
| 82550 | <1% | 356 | $1K | |
| 87088 | <1% | 288 | $1K | |
| 82565 | <1% | 164 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 24 | $1K |
| 83615 | <1% | 230 | $980.40 | |
| 64494 | <1% | 12 | $790.09 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,044 | $764.40 |
| 72100 | <1% | 115 | $761.11 | |
| 73630 | <1% | 326 | $653.27 | |
| 70486 | <1% | 19 | $640.74 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 33 | $631.92 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,350 | $612.30 |
| 73030 | <1% | 285 | $545.73 | |
| 73562 | <1% | 303 | $526.48 | |
| 73610 | <1% | 269 | $521.19 | |
| 87205 | <1% | 213 | $488.68 | |
| 86780 | <1% | 52 | $488.58 | |
| 82570 | <1% | 100 | $405.04 | |
| 96376 | <1% | 2,501 | $353.31 | |
| 73502 | <1% | 40 | $323.69 | |
| 86618 | <1% | 29 | $303.98 | |
| 84100 | <1% | 97 | $257.88 | |
| 82010 | <1% | 25 | $129.47 | |
| 73130 | <1% | 100 | $109.12 | |
| 86762 | <1% | 12 | $90.86 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 277 | $90.56 |
| 86787 | <1% | 14 | $90.28 | |
| 84156 | <1% | 29 | $84.47 | |
| 82272 | <1% | 47 | $75.99 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,927 | $73.48 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 935 | $57.87 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,305 | $50.79 |
| 84134 | <1% | 17 | $39.25 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,122 | $39.13 |
| 86592 | <1% | 12 | $38.76 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,906 | $36.86 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,918 | $36.52 |
| 36410 | <1% | 133 | $15.62 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,613 | $8.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,243 | $5.78 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,916 | $5.62 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 438 | $4.53 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 15 | $1.52 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,506 | $1.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,030 | $0.67 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 478 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 3,655 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,434 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,072 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,938 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,330 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,219 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,022 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 23 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 401 | $0.00 |
| 36416 | 0% | 147 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 114 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 44 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 74 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 84 | $0.00 |
| 88304 | 0% | 12 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 13 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 13 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,439 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 162 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 992 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,074 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,220 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 979 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 26 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 114 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 2,149 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 20 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 14 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 264 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 521 | $0.00 |
| A4565 | Slings | 0% | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 63 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 103 | $0.00 |
| 73140 | 0% | 12 | $0.00 | |
| 73110 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (SVP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.